- New Purchases: IMUX,
- Reduced Positions: REPL, TBIO, PRTK, FGEN, CDTX, EPIX, JNCE, PIRS, SNNA,
- Sold Out: CBAY, DRNA,
For the details of Omega Fund Management (US) Inc.'s stock buys and sells, go to https://www.gurufocus.com/guru/omega+fund+management+%28us%29+inc./current-portfolio/portfolioportfolio
These are the top 5 holdings of Omega Fund Management (US) Inc.- Gossamer Bio Inc (GOSS) - 6,953,416 shares, 48.97% of the total portfolio.
- Replimune Group Inc (REPL) - 5,103,455 shares, 23.68% of the total portfolio. Shares reduced by 50%
- Translate Bio Inc (TBIO) - 2,437,603 shares, 9.78% of the total portfolio. Shares reduced by 50%
- Immunic Inc (IMUX) - 1,371,494 shares, 5.00% of the total portfolio. New Position
- ObsEva SA (OBSV) - 999,364 shares, 3.59% of the total portfolio.
Omega Fund Management (US) Inc. initiated holding in Immunic Inc. The purchase prices were between $7.87 and $33.2, with an estimated average price of $13.15. The stock is now traded at around $13.55. The impact to a portfolio due to this purchase was 5%. The holding were 1,371,494 shares as of .
Sold Out: CymaBay Therapeutics Inc (CBAY)Omega Fund Management (US) Inc. sold out a holding in CymaBay Therapeutics Inc. The sale prices were between $6.05 and $13.66, with an estimated average price of $11.36.
Sold Out: Dicerna Pharmaceuticals Inc (DRNA)Omega Fund Management (US) Inc. sold out a holding in Dicerna Pharmaceuticals Inc. The sale prices were between $10.78 and $15.9, with an estimated average price of $13.58.
Here is the complete portfolio of Omega Fund Management (US) Inc.. Also check out:
1. Omega Fund Management (US) Inc.'s Undervalued Stocks
2. Omega Fund Management (US) Inc.'s Top Growth Companies, and
3. Omega Fund Management (US) Inc.'s High Yield stocks
4. Stocks that Omega Fund Management (US) Inc. keeps buying
